A PCAC recommendation is not a green light
When a peptide gets a favorable committee vote, the marketing gets loud fast. Here is what a vote actually means — and the three steps that stand between it and legal 503A compounding. Monitoring, not legal advice.
- 1
Under review (Category 2 / nominated)
A substance nominated for the 503A Bulks List sits in review. While it is under review — or in Category 2, where FDA has identified safety questions — it is not eligible for 503A compounding.
- 2
PCAC recommendation (a vote, not a rule)
The Pharmacy Compounding Advisory Committee reviews the evidence and votes a recommendation to FDA. FDA is not bound by it, and the recommendation itself changes nothing about what may be compounded. This is a milestone, not a green light.
- 3
Category 1 via notice-and-comment rulemaking
A substance becomes eligible for 503A compounding only when FDA places it on the 503A Bulks List (Category 1) through formal notice-and-comment rulemaking — commonly 8–12 months. Only at that point is compounding permitted.
The bottom line: until a substance is placed in Category 1 by rulemaking, compounding it under 503A is not permitted — no matter what a vendor’s press release says. Med Spa Radar sells no substance and takes no position on any peptide; we report what the record states, with dates and citations.
Where each tracked peptide stands now
Live from the tracker — federal PCAC standing, most recent first. None are in Category 1 (eligible for 503A compounding).
Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
PCAC 07/23/2026 ↗Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding KPV to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
PCAC 07/23/2026 ↗Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding MOTS-c to the FDA 503A Bulks List, 7–5–2 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
PCAC 07/23/2026 ↗Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding TB-500 to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
PCAC 07/23/2026 ↗Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2024-24828 ↗
Sources
Track the standing, not the hype
We watch the Federal Register and FDA and tell you when a peptide’s legal standing actually changes — with the citation.
Get the free Brief →